Front Line Maintenance Options in Advanced Ovarian Cancer

Avutometinib plus defactinib produces no new safety signals among those with low-grade serous ovarian cancer in the phase 2 RAMP 201 trial.

Dr. Dmitriy Zamarin speaks with Cancer Network about the findings of a phase II trial in platinum-resistant ovarian cancer patients.

Maintenance with niraparib also produces benefits in chemotherapy-free interval and time to first and second therapy among those with BRCA wild-type recurrent ovarian cancer in the phase 3 NOVA study.

Dr. Ranjit Manchanda speaks with Cancer Network about using population testing to predict and prevent gynecologic cancers.

Maintenance bevacizumab plus durvalumab and olaparib appears to produce a progression-free survival benefit among those with HRD-negative advanced ovarian cancer in the phase 3 DUO-O trial.

Prexasertib is currently under investigation as part of a phase 2 trial as a treatment for patients with platinum-resistant ovarian cancer, endometrial adenocarcinoma, and urothelial cancers.